ArticleCardiovascular and interventional radiology2025
Revascularization in Nonagenarians with Chronic Limb-Threatening Ischemia Can Be Effective.
Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe average age of patients with Chronic Limb-Threatening Ischemia (CLTI) who are being referred to vascular surgery units is increasing. This study aimed to evaluate clinical outcomes of revascularization (wound healing and cessation of rest pain) in nonagenarians with CLTI and the impact on their initial living status.
methodsThis retrospective, single centre study included patients aged 90 or more who presented with CLTI. Two groups were compared: "treated", who underwent revascularization (open, endovascular or hybrid), versus "not treated", who were treated conservatively. The latter included patients unfit for invasive treatment, with overriding active diseases, hip/knee ankylosis or refusing invasive treatment. Both groups were followed by dedicated wound care specialists. The primary outcomes were wound healing or cessation of rest pain and maintenance of initial living status after discharge. Secondary outcomes were overall mortality and major amputations at 1, 3, 6 and 12 months. Demographics, type of invasive treatment, access related complications and postoperative general complications were collected as well. Wound healing and mortality were assessed using cumulative outcome estimates according to Kaplan-Meier and comparisons using the log-rank test.
resultsBetween 1st January 2018 and 31st July 2023, 123 patients with 131 chronic limb-threatening ischemic limbs were included. The "treated" group included 101 limbs with Rutherford 4 (n = 8,7.9%), 5 (n = 78, 77.2%) and 6 (n = 15, 14.9%) Peripheral Arterial Disease (PAD),. The "not treated" group included 30 limbs with Rutherford 5 (n = 22, 73.3%) and 6 (n = 8, 26.7%) PAD. Treatment consisted of eight open, 86 endovascular and seven hybrid procedures. No primary amputations were conducted. At 1 year, 64.6% (31/48) of the wounds in the "treated" group healed, while non healed in the "not treated" group (p < .001). Eighty-nine (94%) of the treated patients lived at home, and 72/89 (81%) were able to return home after discharge. One-year mortality rates for treated and not treated patients were 31.7% and 63.3%, respectively (p < .001). Access related complications were noted in 6.9% of the nonagenarians and 33.7% had a general adverse event.
conclusionsRevascularization in nonagenarians with CLTI can be effective despite the advanced age. Wound healing is feasible without compromising the initial patient living autonomy and maintaining a low risk of major amputation and an acceptable mortality rate.
Indexed as
Identifiers
40488760What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.